Ribbon diagram of canakinumab (blue) bound to IL-1β (yellow) from PDB entry 5bvp[1]
Monoclonal antibody
Type
Whole antibody
Source
Human
Target
IL-1β
Clinical data
Trade names
Ilaris
Other names
ACZ885, ACZ-885
AHFS/Drugs.com
Monograph
License data
EU EMA: by INN
US DailyMed: Canakinumab
Pregnancy category
AU: B3
Routes of administration
Intravenous, subcutaneous
ATC code
L04AC08 (WHO)
Legal status
Legal status
US: ℞-only[2]
EU: Rx-only[3]
In general: ℞ (Prescription only)
Identifiers
CAS Number
914613-48-2N
DrugBank
DB06168Y
ChemSpider
none
UNII
37CQ2C7X93
KEGG
D09315
ChEMBL
ChEMBL1201834N
Chemical and physical data
Formula
C6452H9958N1722O2010S42
Molar mass
145157.20 g·mol−1
NY (what is this?)(verify)
Canakinumab, sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis, active Still's disease, including adult-onset Still's disease, gout flares.[4][5][6] It is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.[7]
Common side effects include infections (colds and upper respiratory tract infections), abdominal pain and injection-site reactions.[2][3][4]
^Rondeau JM, Ramage P, Zurini M, Gram H (2015). "The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β". mAbs. 7 (6): 1151–1160. doi:10.1080/19420862.2015.1081323. PMC 4966334. PMID 26284424.
^ abCite error: The named reference Ilaris FDA label was invoked but never defined (see the help page).
^ abCite error: The named reference Ilaris EPAR was invoked but never defined (see the help page).
^ ab"FDA Approves First Treatment for Adult Onset Still's Disease, a Severe and Rare Disease". U.S. Food and Drug Administration (FDA) (Press release). 16 June 2020. Retrieved 16 June 2020. This article incorporates text from this source, which is in the public domain.
^"FDA Approves Canakinumab for Gout Flares". Medscape. Retrieved 1 September 2023.
^Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. (June 2009). "Use of canakinumab in the cryopyrin-associated periodic syndrome". The New England Journal of Medicine. 360 (23): 2416–2425. doi:10.1056/NEJMoa0810787. PMID 19494217.
Canakinumab, sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis, active Still's disease, including...
Treatments may include corticosteroids, ciclosporin, infliximab, or canakinumab. The disease was identified in 1930. It affects approximately 1 person...
pharmaceutical drug Canakinumab was conducted. In this study, canakinumab was effective in patients with YAOS, and thus clinical trial of canakinumab may be warranted...
The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) reported in late 2017 that inflammation inhibition with Canakinumab, a monoclonal...
adding anakinra to the daily colchicine regimen has been successful. Canakinumab, an anti-interleukin-1-beta monoclonal antibody, has likewise been shown...
immunosuppressant into an area such as the lower abdomen. The monoclonal antibody canakinumab (Ilaris) is also used. When the body is exposed to the cold in individuals...
interleukin 1; they cannot be taken in tablet form. These are anakinra, canakinumab and rilonacept. Rilonacept has been specifically approved as an orphan...
are under study for treating gout, including anakinra, canakinumab, and rilonacept. Canakinumab may result in better outcomes than a low dose of a glucocorticoid...
target for treatment of diabetic retinopathy. However, systemic using of canakinumab did not have an significant effect. The role of IL-1β in age-related...
future the febrile attacks start. (Examined in a 12-year-old patient). Canakinumab is a long acting monoclonal antibody which is directed against IL-1β...
therapeutic target, and medications such as anakinra, rilonacept, and canakinumab have revolutionized the treatment of autoinflammatory diseases.[citation...
inhibitors are not effective, Interleukin-1 inhibitors (e.g., anakinra, canakinumab, rilonacept) and interleukin-6 inhibitors (e.g., tocilizumab) may be...
inhibitors, interferon alpha may be effective. A 2020 review reported that canakinumab was "an effective long-term treatment with a favorable safety profile...
Global Information
(what is this?) (verify)
This article incorporates text from this source, which is in the public domain.
